Human Intestinal Transporter Database: QSAR Modeling and Virtual Profiling of Drug Uptake, Efflux and Interactions
暂无分享,去创建一个
A. Tropsha | Alexander Sedykh | D. Fourches | J. Duan | O. Hucke | M. Garneau | Hao Zhu | P. Bonneau
[1] Hai Yang,et al. ACM Transactions on Intelligent Systems and Technology - Special Section on Urban Computing , 2014 .
[2] F. Van Bambeke,et al. ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions. , 2011, Current drug targets.
[3] Chih-Jen Lin,et al. LIBSVM: A library for support vector machines , 2011, TIST.
[4] Tudor I. Oprea,et al. A novel approach for predicting P-glycoprotein (ABCB1) inhibition using molecular interaction fields. , 2011, Journal of medicinal chemistry.
[5] Michael Wiese,et al. Structure-activity relationships of flavonoids as inhibitors of breast cancer resistance protein (BCRP). , 2011, Bioorganic & medicinal chemistry.
[6] David S. Wishart,et al. DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..
[7] G. Szakács,et al. Understanding transport through pharmacological barriers — are we there yet? , 2010, Nature Reviews Drug Discovery.
[8] Alexander Tropsha,et al. Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..
[9] Alexander Tropsha,et al. Best Practices for QSAR Model Development, Validation, and Exploitation , 2010, Molecular informatics.
[10] Alexander D. MacKerell,et al. Molecular switch controlling the binding of anionic bile acid conjugates to human apical sodium-dependent bile acid transporter. , 2010, Journal of medicinal chemistry.
[11] Ligong Chen,et al. Pharmacogenomics of membrane transporters: past, present and future. , 2010, Pharmacogenomics.
[12] M. Niemi,et al. Membrane transporters in drug development , 2010, Nature Reviews Drug Discovery.
[13] X. Ming,et al. Role of basolateral efflux transporter MRP4 in the intestinal absorption of the antiviral drug adefovir dipivoxil. , 2010, Biochemical pharmacology.
[14] Sean Ekins,et al. Computational models for drug inhibition of the human apical sodium-dependent bile acid transporter. , 2009, Molecular pharmaceutics.
[15] Marilyn E. Morris,et al. Structure–Activity Relationships and Quantitative Structure–Activity Relationships for Breast Cancer Resistance Protein (ABCG2) , 2009, The AAPS Journal.
[16] Leslie Z. Benet,et al. The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs , 2009, Pharmaceutical Research.
[17] Ulf Norinder,et al. Identification of Novel Specific and General Inhibitors of the Three Major Human ATP-Binding Cassette Transporters P-gp, BCRP and MRP2 Among Registered Drugs , 2009, Pharmaceutical Research.
[18] Andreas Maunz,et al. Development of decision tree models for substrates, inhibitors, and inducers of p-glycoprotein. , 2009, Current drug metabolism.
[19] Hui Zhang,et al. Support vector machine and pharmacophore-based prediction models of multidrug-resistance protein 2 (MRP2) inhibitors. , 2009, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[20] Charles Elkan,et al. The Transporter Classification Database: recent advances , 2008, Nucleic Acids Res..
[21] Li Di,et al. Permeability--in vitro assays for assessing drug transporter activity. , 2008, Current drug metabolism.
[22] Christel A. S. Bergström,et al. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. , 2008, Journal of medicinal chemistry.
[23] N. Tawari,et al. Pharmacophore mapping of a series of pyrrolopyrimidines, indolopyrimidines and their congeners as multidrug-resistance-associated protein (MRP1) modulators , 2008, Journal of molecular modeling.
[24] Christel A. S. Bergström,et al. Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2). , 2008, Journal of medicinal chemistry.
[25] Lars Olsen,et al. QSAR Models for the Human H+/Peptide Symporter, hPEPT1: Affinity Prediction Using Alignment-Independent Descriptors , 2008, J. Chem. Inf. Model..
[26] Alexander Golbraikh,et al. Predictive QSAR modeling workflow, model applicability domains, and virtual screening. , 2007, Current pharmaceutical design.
[27] Ulf Norinder,et al. A Global Drug Inhibition Pattern for the Human ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (ABCG2) , 2007, Journal of Pharmacology and Experimental Therapeutics.
[28] Gerta Rücker,et al. y-Randomization and Its Variants in QSPR/QSAR , 2007, J. Chem. Inf. Model..
[29] W. Haefeli,et al. Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by Nucleoside, Nucleotide, and Non-Nucleoside Reverse Transcriptase Inhibitors , 2007, Drug Metabolism and Disposition.
[30] Jurre J. Kamphorst,et al. A performance evaluation of multiple classification models of human PEPT1 inhibitors and non‐inhibitors , 2007 .
[31] Ian T. Paulsen,et al. TransportDB: a comprehensive database resource for cytoplasmic membrane transport systems and outer membrane channels , 2006, Nucleic Acids Res..
[32] Tingjun Hou,et al. ADME Evaluation in Drug Discovery, 7. Prediction of Oral Absorption by Correlation and Classification , 2007, J. Chem. Inf. Model..
[33] Sean Ekins,et al. Pharmacophore-based discovery of ligands for drug transporters. , 2006, Advanced drug delivery reviews.
[34] Gerald M. Maggiora,et al. On Outliers and Activity Cliffs-Why QSAR Often Disappoints , 2006, J. Chem. Inf. Model..
[35] B. Vig,et al. Human PEPT1 pharmacophore distinguishes between dipeptide transport and binding. , 2006, Journal of medicinal chemistry.
[36] Peter W Swaan,et al. Computational approaches to modeling drug transporters. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[37] Miguel A. Cabrera,et al. A topological substructural approach for the prediction of P-glycoprotein substrates. , 2006, Journal of pharmaceutical sciences.
[38] A. Ross,et al. Monocarboxylate transporter MCT1 is a target for immunosuppression , 2005, Nature chemical biology.
[39] B. Lum,et al. Quantitative structure-activity relationships of methotrexate and methotrexate analogues transported by the rat multispecific resistance-associated protein 2 (rMrp2). , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[40] A. Madan,et al. Topological model for the prediction of MRP1 inhibitory activity of pyrrolopyrimidines and templates derived from pyrrolopyrimidine. , 2005, Bioorganic & medicinal chemistry letters.
[41] M. Brandsch,et al. Three-dimensional quantitative structure-activity relationship analyses of beta-lactam antibiotics and tripeptides as substrates of the mammalian H+/peptide cotransporter PEPT1. , 2005, Journal of medicinal chemistry.
[42] Ronen Feldman,et al. The Data Mining and Knowledge Discovery Handbook , 2005 .
[43] Lior Rokach,et al. Data Mining And Knowledge Discovery Handbook , 2005 .
[44] Nitesh V. Chawla,et al. Data Mining for Imbalanced Datasets: An Overview , 2005, The Data Mining and Knowledge Discovery Handbook.
[45] N. Ozawa,et al. Transporter Database, TP-Search: A Web-Accessible Comprehensive Database for Research in Pharmacokinetics of Drugs , 2004, Pharmaceutical Research.
[46] Leo Breiman,et al. Random Forests , 2001, Machine Learning.
[47] Leonard E. Trigg,et al. Technical Note: Naive Bayes for Regression , 2000, Machine Learning.
[48] Tingjun Hou,et al. ADME evaluation in drug discovery , 2002, Journal of molecular modeling.
[49] Alexander Golbraikh,et al. Quantitative Structure−Activity Relationship Analysis of Functionalized Amino Acid Anticonvulsant Agents Using k Nearest Neighbor and Simulated Annealing PLS Methods , 2002 .
[50] J. Polli,et al. Rational use of in vitro P-glycoprotein assays in drug discovery. , 2001, The Journal of pharmacology and experimental therapeutics.
[51] Elazer R. Edelman,et al. Adv. Drug Delivery Rev. , 1997 .